A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
NCT ID: NCT03231449
Last Updated: 2018-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2017-02-01
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease
NCT07257289
Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study
NCT02128139
Clinical Course of Coronary Artery Disease Among Blacks
NCT00005191
Framingham Heart Study
NCT00005121
National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups
NCT00699959
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
FEVRIER evaluates the modalities of care management. It will take place in cardiology units of hospitals of sub-Saharian countries one month per year (month of February) during 5 years.
The investigator will thoroughly complete:
* one information form describing the hospital and the department
* one questionnaire (2o questions) for each hospitalized patient
Patients with at least one day of hospitalization will be enrolled in the study. On the first day of February, all patients already hospitalized will be enrolled and all patients hospitalized in the last day of February will be followed until their discharge. thus, data collection will start 1st day of investigation, during February and will continue until the discharge of the last enrolled patient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observation of current care
The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Cardiologie et Développement
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xavier Jouven
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier Jouven, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
cardiologie et Developpement
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre national hospitalier et universitaire Koutoukou Maga
Cotonou, , Benin
Centre médical Paul IV
Ouagadougou, , Burkina Faso
Hopital militaire de Kamenge et polyclinique maison médicale
Bujumbura, , Burundi
Hôpital Régional
Bafoussam, , Cameroon
Douala General Hospital
Douala, , Cameroon
Central Hospital
Yaoundé, , Cameroon
Hôpital Général de Yaoundé
Yaoundé, , Cameroon
Institut de Cariologie d'Abidjan
Abidjan, , Côte d’Ivoire
CHU
Bouaké, , Côte d’Ivoire
Clinique Ngaliema
Kinshasa, , Democratic Republic of the Congo
Clinique universitaire de Kinshasa
Kinshasa, , Democratic Republic of the Congo
Centre Hospitalier Universitaire (CHUL)
Libreville, , Gabon
CHU Ignace Deen
Conakry, , Guinea
Institut du coeur
Maputo, , Mozambique
Hôpital National Lamorde
Niamey, , Niger
CHU
Brazzaville, , Republic of the Congo
Hôpital de Fann
Dakar, , Senegal
Hôpital général de Grand Yoff
Dakar, , Senegal
El Hadj-Ibrahima Niass
Kaolack, , Senegal
National Cardiothoracic center / Shab Teaching Hospital
Khartoum, , Sudan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Jani D, Paquet C, Jacob S, Sidi D, Jouven X. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007 Aug 2;357(5):470-6. doi: 10.1056/NEJMoa065085.
Marijon E, Celermajer DS, Tafflet M, El-Haou S, Jani DN, Ferreira B, Mocumbi AO, Paquet C, Sidi D, Jouven X. Rheumatic heart disease screening by echocardiography: the inadequacy of World Health Organization criteria for optimizing the diagnosis of subclinical disease. Circulation. 2009 Aug 25;120(8):663-8. doi: 10.1161/CIRCULATIONAHA.109.849190. Epub 2009 Aug 10.
Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012 Mar 10;379(9819):953-964. doi: 10.1016/S0140-6736(11)61171-9.
Ranque B, Menet A, Diop IB, Thiam MM, Diallo D, Diop S, Diagne I, Sanogo I, Kingue S, Chelo D, Wamba G, Diarra M, Anzouan JB, N'Guetta R, Diakite CO, Traore Y, Legueun G, Deme-Ly I, Belinga S, Boidy K, Kamara I, Tharaux PL, Jouven X. Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study. Lancet Haematol. 2014 Nov;1(2):e64-73. doi: 10.1016/S2352-3026(14)00007-6. Epub 2014 Oct 28.
Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Sidi D, Jouven X. Echocardiographic screening for rheumatic heart disease. Bull World Health Organ. 2008 Feb;86(2):84. doi: 10.2471/blt.07.046680. No abstract available.
Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear S, Anand S, Wielgosz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Iqbal R, Rahman O, Rosengren A, Yusufali A, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Oguz A, McQueen M, McKee M, Dagenais G; PURE Investigators. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014 Aug 28;371(9):818-27. doi: 10.1056/NEJMoa1311890.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.